U.S. Semiconductors Stock News

W. R. Berkley (WRB) posted net profit margins of 13% for the recent period, improving from 12% a year ago. Earnings surged 20.8% over the past year, outpacing the company’s five-year annual average growth of 19%. The combination of rising profits and stronger margins grabs attention. However, with revenue projected to grow just 1.6% per year and earnings at 1.5%, both trailing the broader US market, investors may question whether the current momentum is sustainable as the company trades at a...

Equifax (EFX) delivered a notable turnaround this earnings season, with EPS climbing 17.1% year-over-year after recording a five-year average annual decline of 1.2%. Net profit margins also ticked upward to 11.1%, up from 10.1% a year earlier, underscoring an improvement in profitability. Looking ahead, the market is eyeing robust growth drivers as forecasts call for annual EPS growth of 20.24% over the next three years, which would outpace expectations for the broader US market. See our full...

Janus International Group (JBI) has caught the attention of investors after S&P Global Ratings upgraded the company’s credit rating from "B+" to "BB-" with a stable outlook. This shift highlights the company’s steady business model, low net leverage, and reliable cash flow. See our latest analysis for Janus International Group. The S&P rating upgrade comes on the heels of upbeat quarterly earnings and a $75 million share repurchase program, both of which signal management’s ongoing...

Thinking about what to do with H2O America stock? You are not alone; investors have been closely watching its price swings and wondering whether the water services company is truly undervalued or if there is more turbulence ahead. Over the past week, H2O America delivered a notable 6.3% rally, and even though it remains up 4.4% for the month, the bigger picture shows shares are recovering from a tough patch. The stock is still down 10.6% over the last year and nearly 15.2% over three years,...

GATX (GATX) reported a net profit margin of 18.1%, edging above last year’s 17.4%. Earnings are forecasted to grow at 11.2% annually, with revenue set for 5.4% yearly growth. These figures trail the broader US market’s projected pace. Recent earnings were also boosted by a one-off gain of $125.0 million. With the company’s share price currently at $163.02, investors face a mix of decelerating growth and solid profitability. This dynamic is likely to shape sentiment as they weigh short-term...

Crown Holdings (NYSE:CCK) reported a sharp jump in net profit margins to 7.8%, up from just 0.8% a year earlier. Over the past year, EPS growth soared by 865.3%, easily outpacing the company’s 15.6% average annual growth over the past five years. Revenue is expected to rise by 3.1% per year going forward, trailing the broader US market growth forecast, and shares now trade at a 12x Price-To-Earnings Ratio, below industry averages. The latest results underline profitable momentum, but slower...

This week’s picks cover: How UPS plans to cut costs and automate its way back to profitability, why Paradigm Biopharma could soar if its osteoarthritis drug wins FDA approval, and how Barrick Mining offers a hedge against U.S. fiscal chaos

Rexford Industrial Realty (REXR) reported net profit margins of 32.9%, up from 29.3% last year, highlighting robust profitability. While the company’s earnings have grown at an impressive 29.3% per year over the past five years, growth cooled to 23.8% in the most recent year. Future projections indicate a 1.6% annual earnings decline and 5.1% revenue growth, which lags behind the broader US market. Results were buoyed by an $80.1 million one-off gain, and the shares currently trade at $43.41,...

Perspective Therapeutics revealed updated interim results from its Phase 1/2a trial of [212Pb]VMT-alpha-NET at ESMO Congress 2025, which sparked a sharp drop in the company’s share price as investors digested the latest efficacy signals. See our latest analysis for Perspective Therapeutics. This latest clinical trial update comes after a challenging year for Perspective Therapeutics. Following a brief rally in anticipation of new data, the 1-day share price return slipped by 2.5%, and the...

Artiva Biotherapeutics recently announced that the FDA has granted Fast Track Designation to its AlloNK (AB-101) therapy in combination with rituximab for the treatment of refractory rheumatoid arthritis, marking a first for deep B-cell depleting therapies in this indication. This development highlights Artiva's focus on addressing a large unmet need in autoimmune disease with an outpatient-ready, community-administered cellular therapy. We'll explore how Fast Track status for AlloNK and...

Key Insights Significantly high institutional ownership implies Vir Biotechnology's stock price is sensitive to their...

While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock...

With a price-to-earnings (or "P/E") ratio of 7x Dream Finders Homes, Inc. ( NYSE:DFH ) may be sending very bullish...

Nordic American Tankers (NYSE:NAT) has had a great run on the share market with its stock up by a significant 27% over...

As the Dow Jones Industrial Average reaches an all-time high amidst a flurry of corporate earnings reports, investors are keenly observing the broader U.S. market's performance against a backdrop of ongoing government shutdown and trade discussions with China. In this environment, identifying undervalued stocks becomes crucial for those looking to capitalize on potential opportunities that may arise from discrepancies between current stock prices and their intrinsic value.

Most readers would already be aware that Teekay's (NYSE:TK) stock increased significantly by 11% over the past three...

As the Dow Jones Industrial Average reaches an all-time high amid a flurry of robust earnings reports, the broader U.S. market is experiencing a wave of optimism despite ongoing economic challenges such as the government shutdown. In this environment, identifying stocks with strong fundamentals and growth potential can be particularly rewarding, especially as investors look beyond well-known names to uncover hidden opportunities within the market.

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

United States Lime & Minerals, Inc.'s ( NASDAQ:USLM ) price-to-earnings (or "P/E") ratio of 30.9x might make it look...

We can readily understand why investors are attracted to unprofitable companies. For example, Palladyne AI...

With a price-to-earnings (or "P/E") ratio of 4.2x MV Oil Trust ( NYSE:MVO ) may be sending very bullish signals at the...

Key Insights Institutions' substantial holdings in Axogen implies that they have significant influence over the...

Dorman Products, Inc. ( NASDAQ:DORM ), is not the largest company out there, but it led the NASDAQGS gainers with a...

Key Insights Insiders appear to have a vested interest in Waton Financial's growth, as seen by their sizeable ownership...